Norway · Delayed Price · Currency is NOK Thor Medical ASA Statistics
Total Valuation
OSL:TRMED has a market cap or net worth of NOK 1.99 billion. The enterprise value is 2.17 billion.
| Market Cap | 1.99B |
| Enterprise Value | 2.17B |
Important Dates
The last earnings date was Friday, August 28, 2026.
| Earnings Date | Aug 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
OSL:TRMED has 422.50 million shares outstanding. The number of shares has increased by 29.88% in one year.
| Current Share Class | 422.50M |
| Shares Outstanding | 422.50M |
| Shares Change (YoY) | +29.88% |
| Shares Change (QoQ) | +1.10% |
| Owned by Insiders (%) | 7.40% |
| Owned by Institutions (%) | 7.31% |
| Float | 208.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,211.57 |
| PB Ratio | 4.84 |
| P/TBV Ratio | 12.78 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.89, with a Debt / Equity ratio of 0.59.
| Current Ratio | 2.89 |
| Quick Ratio | 1.85 |
| Debt / Equity | 0.59 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.02 |
| Interest Coverage | -8.54 |
Financial Efficiency
Return on equity (ROE) is -18.79% and return on invested capital (ROIC) is -9.13%.
| Return on Equity (ROE) | -18.79% |
| Return on Assets (ROA) | -8.06% |
| Return on Invested Capital (ROIC) | -9.13% |
| Return on Capital Employed (ROCE) | -12.13% |
| Weighted Average Cost of Capital (WACC) | 2.98% |
| Revenue Per Employee | 68,292 |
| Profits Per Employee | -3.46M |
| Employee Count | 24 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -4.26M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +21.76% in the last 52 weeks. The beta is -0.24, so OSL:TRMED's price volatility has been lower than the market average.
| Beta (5Y) | -0.24 |
| 52-Week Price Change | +21.76% |
| 50-Day Moving Average | 5.23 |
| 200-Day Moving Average | 4.74 |
| Relative Strength Index (RSI) | 36.52 |
| Average Volume (20 Days) | 11,020,083 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, OSL:TRMED had revenue of NOK 1.64 million and -83.01 million in losses. Loss per share was -0.23.
| Revenue | 1.64M |
| Gross Profit | 1.64M |
| Operating Income | -82.85M |
| Pretax Income | -87.27M |
| Net Income | -83.01M |
| EBITDA | -60.13M |
| EBIT | -82.85M |
| Loss Per Share | -0.23 |
Balance Sheet
The company has 59.90 million in cash and 242.20 million in debt, with a net cash position of -182.30 million or -0.43 per share.
| Cash & Cash Equivalents | 59.90M |
| Total Debt | 242.20M |
| Net Cash | -182.30M |
| Net Cash Per Share | -0.43 |
| Equity (Book Value) | 410.10M |
| Book Value Per Share | 1.14 |
| Working Capital | 77.00M |
Cash Flow
In the last 12 months, operating cash flow was -90.94 million and capital expenditures -145.81 million, giving a free cash flow of -236.75 million.
| Operating Cash Flow | -90.94M |
| Capital Expenditures | -145.81M |
| Depreciation & Amortization | 22.72M |
| Net Borrowing | 59.42M |
| Free Cash Flow | -236.75M |
| FCF Per Share | -0.56 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -5,055.09% |
| Pretax Margin | -5,324.47% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
OSL:TRMED does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -29.88% |
| Shareholder Yield | -29.88% |
| Earnings Yield | -4.18% |
| FCF Yield | -11.92% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
OSL:TRMED has an Altman Z-Score of 2.14. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.14 |
| Piotroski F-Score | n/a |